Trial Profile

A Multi-center Clinical Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T (CAR-T) Cell Injection (CT103A) in the Treatment of Newly Diagnosed Subjects With High-risk Multiple Myeloma (FUMANBA-2)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Jun 2024 According to a Nanjing IASO Biotherapeutics media release, as of January 25th, 2024, 16 subjects received Eque-cel therapy.
15 Jun 2024 Results presented in the Nanjing IASO Biotherapeutics Media Release.
15 Jun 2024 According to a Nanjing IASO Biotherapeutics media release, results from this trial were presented at the 2024 European Hematology Association (EHA) Annual Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com